Levosimendan - A calcium sensitising agent with potential anti-arrhythmic properties

International Journal of Clinical Practice

Volumn 64, Issue 8, 2010, Pages 1148-1154

  Kowalczyk, M ^a   Banach, M ^a   Lip, G Y H ^b   Kozlowski D ^c   Mikhailidis, D P ^d   Rysz, J ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c MEDICAL UNIVERSITY OF GDANSK   (Poland)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM ION; DOBUTAMINE; DRUG METABOLITE; INTERLEUKIN 6; LEVOSIMENDAN; MALONALDEHYDE; N [4 (1,4,5,6 TETRAHYDRO 4 METHYL 6 OXO 3 PYRIDAZINYL)PHENYL]ACETAMIDE; NORADRENALIN; OR 1855; PLACEBO; UNCLASSIFIED DRUG;

ACUTE HEART FAILURE; ANTIARRHYTHMIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARRHYTHMOGENESIS; CARDIOGENIC SHOCK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY OBSTRUCTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEMODYNAMICS; HUMAN; KIDNEY FAILURE; LIVER FAILURE; PRIORITY JOURNAL; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; SYSTEMATIC REVIEW; VASODILATATION;

ANTI-ARRHYTHMIA AGENTS; ANTI-INFLAMMATORY AGENTS; ARRHYTHMIAS, CARDIAC; ATRIAL FIBRILLATION; CARDIOTONIC AGENTS; HEART FAILURE; HUMANS; HYDRAZONES; PYRIDAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77953867363     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2010.02396.x     Document Type: Review

References (62)

1. Haikala H, Pollesello P. Calcium sensitivity enhancers. IDrugs 2000 3 : 1199 1205.
2. Antoniades C, Tousoulis D, Koumallos N, Marinou K, Stefanadis C. Levosimendan: beyond its simple inotropic effect in heart. Pharmacol Ther 2007 114 : 184 197.
3. ++ sensitizers impair cardiac relaxation in failing human myocardium. J Pharmacol Exp Ther 1997 208 : 247 254.
4. Haikala H, Nissinen E, Etemadzadeh E, Levijoki J, Linden IB. Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation. J Cardiovasc Pharmacol 1995 25 : 794 801.
5. Aronow WS, Banach M. Atrial fibrillation: the new epidemic of the ageing world. J Atrial Fibrillation 2009 1 : 337 361.
6. Heist EK, Ruskin JN. Atrial fibrillation and congestive heart failure: risk factors, mechanisms, and treatment. Prog Cardiovasc Dis 2006 48 : 256 269.
7. Pang PS, Ghorghiade M. Special cases in acute heart failure syndromes: atrial fibrillation and wide complex tachycardia. Heart Failure Clinic 2009 5 : 113 123.
8. + channel in rat arterial myocytes. Eur J Pharmacol 1997 333 : 249 259. (Pubitemid 27387398)
9. Kersten JR, Montgomery MW, Pagel PS, Warltier DC. Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels. Anesth Analg 2000 90 : 5 11.
10. Nieminen MS, Akkila J, Hasenfuss G et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 2000 36 : 1903 1912.
11. Slawsky MT, Colucci WS, Gottlieb SS et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation 2000 102 : 2222 2227.
12. Banach M, Kourliouros A, Reinhart KM et al. Postoperative atrial fibrillation - what do we really know? Curr Vasc Pharmacol 2010 8 in press).
13. Mebazaa A, Nieminen MS, Filippatos GS et al. Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE. Eur J Heart Fail 2009 11 : 304 311.
14. Haikala H, Kaheinen P, Levijoki J, Linden IB. The role of cAMP- and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan. Cardiovasc Res 1997 34 : 536 546.
15. 2+-sensitizing effect but not to stereoselective phosphodiesterase inhibition. Basic Clin Pharmacol Toxicol 2006 98 : 74 8.
16. Mebazaa A, Delgado JF, Franco F et al. Levosimendan in the treatment of AHF: lessons from surveys and clinical trials. Eur J Heart Fail Suppl 2008 7 : 228 233.
17. Haikala H, Linden IB. Mechanisms of action of calcium sensitizing drugs. J Cardiovasc Pharmacol 1995 26 (Suppl. 1 S10 9.
18. Antila S, Kivikko M, Lehtonen L et al. Pharmacokinetics of levosimendan and its circulating metabolites in patients with heart failure after an extended continuous infusion of levosimendan. Br J Clin Pharmacol 2004 57 : 412 415. (Pubitemid 38519645)
19. Kivikko M, Antila S, Eha J, Lehtonen L, Pentikainen PJ. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure. J Clin Pharmacol 2002 42 : 43 51. (Pubitemid 34038369)
20. Kivikko M, Antila S, Eha J, Lehtonen L, Pentikainen PJ. Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure. Int J Clin Pharmacol Ther 2002 40 : 465 471. (Pubitemid 35153452)
21. Toller WG, Stranz C. Levosimendan, a new inotropic and vasodilator agent. Anesthesiology 2006 104 : 556 569.
22. Follath F, Cleland JG, Just H et al. Steering Committee and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002 360 : 196 202.
23. Figgitt DP, Gillies PS, Goa KL. Levosimendan. Drugs 2001 61 : 613 627.
24. Moiseyev VS, Põder P, Andrejevs N et al. RUSSLAN Study Investigators. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 2002 23 : 1422 1432.
25. Cleland JG, Freemantle N, Coletta AP, Clark AL. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail 2006 8 : 105 110.
26. Nieminen MS, Cleland JG, Eha J et al. Oral levosimendan in patients with severe chronic heart failure - the PERSIST study. Eur J Heart Fail 2008 10 : 1246 1254.
27. Follath F, Franco F, Cardoso JS. European experience on the practical use of levosimendan in patients with acute heart failure syndromes. Am J Cardiol 2005 96 (Suppl. 80G 5G.
28. Lilleberg J, Ylonen V, Lehtonen L, Toivonen L. The calcium sensitizer levosimendan and cardiac arrhythmias: an analysis of the safety database of heart failure treatment studies. Scand Cardiovasc J 2004 38 : 80 4.
29. Piechota M, Banach M, Jacoń A, Rysz J. Natriuretic peptides in cardiovascular diseases. Cell Mol Biol Lett 2008 13 : 155 181.
30. Plochl W, Rajek A. The use of the novel calcium sensitizer levosimendan in critically ill patients. Anaesth Intensive Care 2004 32 : 471 475.
31. Caimmi PP, Grossini E, Molinari C, Vacca G, Teodori G. Intracoronary infusion of levosimendan to treat postpericardiotomy heart failure. Ann Thorac Surg 2006 82 : e33 4.
32. Brezina A, Riha H, Pirk J. Prophylactic application of levosimendan in cardiac surgical patients with severe left ventricle dysfunction. Exp Clin Cardiol 2009 14 (2 e31 4.
33. Grossini E, Caimmi PP, Molinari C, Teodori G, Vacca G. Hemodynamic effect of intracoronary administration of levosimendan in the anesthetized pig. J Cardiovasc Pharmacol 2005 46 : 333 342.
34. Choi YH, Cowan DB, Wahlers TC, Hetzer R, Del Nido PJ, Stamm C. Calcium sensitisation impairs diastolic relaxation in post-ischaemic myocardium: implications for the use of Ca(2+) sensitising inotropes after cardiac surgery. Eur J Cardiothorac Surg 2010 37 (2 376 383.
35. Rump AF, Acar D, Rosen R, Klaus W. Functional and antiischaemic effects of the phosphodiesterase inhibitor levosimendan in isolated rabbit hearts. Pharmacol Toxicol 1994 74 : 244 248. (Pubitemid 24154962)
36. Raja SG, Rayen BS. Levosimendan in cardiac surgery: current best available evidence. Ann Thorac Surg 2006 81 : 1536 1546.
37. Kaptan K, Erinç K, Ifran A et al. Levosimendan has an inhibitory effect on platelet function. Am J Hematol 2008 83 : 46 9.
38. Mebazaa A, Barraud D, Welschbillig S. Randomized clinical trials with levosimendan. Am J Cardiol 2005 96 (6A 74G 9G.
39. Korantzopoulos P, Kolettis T, Siogas K, Goudevenos J. Atrial fibrillation and electrical remodeling: the potential role of inflammation and oxidative stress. Med Sci Monit 2003 9 : RA225 9.
40. Boos CJ, Lip GY. Inflammation and atrial fibrillation: cause or effect? Heart 2008 94 : 133 134.
41. Korantzopoulos P, Kolettis TM, Galaris D, Goudevenos JA. The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation. Int J Cardiol 2007 115 : 135 143.
42. Banach M, Misztal M, Goch A, Rysz J, Goch JH. Predictors of atrial fibrillation in patients following isolated surgical revascularization. A metaanalysis of 9 studies with 28 786 patients. Arch Med Sci 2007 3 : 229 239.
43. Parissis JT, Andreadou I, Markantonis SL et al. Effects of levosimendan on circulating markers of oxidative and nitrosative stress in patients with advanced heart failure. Atherosclerosis 2007 195 : e210 5.
44. 2+-sensitizer levosimendan improves oxidative damage. BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine. Eur J Heart Fail 2005 7 : 882 887.
45. Kopustinskiene DM, Pollesello P, Saris NE. Levosimendan is a mitochondrial K(ATP) channel opener. Eur J Pharmacol 2001 428 : 311 314.
46. Trikas A, Antoniades C, Latsios G et al. Long-term effects of levosimendan infusion on inflammatory processes and sFas in patients with severe heart failure. Eur J Heart Fail 2006 8 : 804 809.
47. De Hert SG, Lorsomradee S, vanden Eede H, Cromheecke S, Van der Linden PJ. A randomized trial evaluating different modalities of levosimendan administration in cardiac surgery patients with myocardial dysfunction. J Cardiothorac Vasc Anesth 2008 22 : 699 705.
48. Hasenfuss G, Pieske B, Castell M, Kretschmann B, Maier LS, Just H. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation 1998 98 : 2141 2147.
49. + channel in rat ventricular cells. J Pharmacol Exp Ther 1997 283 : 375 383.
50. Liu T, Li G, Xu G. Levosimendan may prevent postoperative atrial fibrillation through anti-inflammatory and antioxidant modulation. J Cardiothorac Vasc Anesth 2009 23 : 757 758.
51. Zangrillo A, Biondi-Zoccai G, Mizzi A et al. Levosimendan reduces cardiac troponin release after cardiac surgery: a meta-analysis of randomized controlled studies. J Cardiothorac Vasc Anesth 2009 23 : 474 478.
52. Landoni G, Mizzi A, Biondi-Zoccai G et al. Reducing mortality in cardiac surgery with levosimendan: a meta-analysis of randomized controlled trials. J Cardiothorac Vasc Anesth 2010 24 (1 51 7.
53. Cardoso JS, Ferreira J, de Sá EP et al. Levosimendan in daily intensive care practice - the experience of 15 centers. Background, methods and organization of the PORTLAND study. Rev Port Cardiol 2004 23 : 1431 1443.
54. Mebazaa A, Nieminen MS, Packer M et al. SURVIVE Investigators. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 2007 297 : 1883 1891.
55. Toivonen L, Viitasalo M, Sundberg S, Akkila J, Lehtonen L. Electrophysiologic effects of a calcium sensitizer inotrope levosimendan. J Cardiovasc Pharmacol 2000 35 : 664 669.
56. Papp JG, Pollesello P, Varro AF, Vegh AS. Effect of levosimendan and milrinone on regional myocardial ischemia/reperfusion-induced arrhythmias in dogs. J Cardiovasc Pharmacol Ther 2006 11 : 129 135.
57. Nijhawan N, Nicolosi AC, Montgomery MW, Aggarwal A, Pagel PS, Warltier DC. Levosimendan enhances cardiac performance after cardiopulmonary bypass: a prospective, randomized placebo-controlled trial. J Cardiovasc Pharmacol 1999 34 : 219 228.
58. Nony P, Boissel JP, Lievre M et al. Evaluation of the effect of phosphodiesterase inhibitors on mortality in chronic heart failure patients: a meta-analysis. Eur J Clin Pharmacol 1994 46 : 191 196.
59. Effects of oral levosimendan on ambulatory electrocardiographic variables. http://clinicaltrials.gov/ct2/show/NCT00698763 (accessed November 2009).
60. Banach M, Rysz J, Drozdz JA et al. Risk factors of atrial fibrillation following coronary artery bypass grafting: a preliminary report. Circ J 2006 70 : 438 441.
61. Banach M, Goch A, Misztal M, Rysz J, Jaszewski R, Goch JH. Predictors of paroxysmal atrial fibrillation in patients undergoing aortic valve replacement. J Thorac Cardiovasc Surg 2007 134 : 1569 1576.
62. Bielecka-Dabrowa A, Goch JH, Rysz J et al. Influence of co-existing atrial fibrillation on the efficacy of atorvastatin treatment in patients with dilated cardiomyopathy: a pilot study. Lipids Health Dis 2009 9 : 21.